Soleno Therapeutics Acquired by Neurocrine Biosciences | Healthcare M&A Deal

Neurocrine Biosciences has completed the acquisition of Soleno Therapeutics, a substance abuse treatment business in the healthcare sector, for $2.9 billion. Neurocrine Biosciences acquisitions expand its endocrinology and rare disease portfolio while adding Soleno’s therapeutics capabilities relevant to substance abuse treatment. Soleno Therapeutics develops medicines aimed at addressing addiction and related behavioral health needs, supporting Neurocrine’s broader healthcare M&A strategy. The merger acquisition is a strategic acquisition by a public biopharma buyer, with deal size reported at $2.9 billion and completion status marked closed.